The Preparation Phase of Psychedelic-Assisted Therapy: What It Is, Why It Matters

Psychedelic-assisted therapy is delivered in three phases: preparation, dosing, and integration. The preparation phase is everything that happens before the first dosing session: medical screening, history review, medication taper planning, therapeutic-alliance building, psychoeducation, intention-setting, and safety screening. This article is a Canadian guide to what preparation looks like, why it is foundational rather than optional, and how preparation differs across ketamine, psilocybin, and MDMA-assisted therapy.

Key takeaways

• Three-phase model: psychedelic-assisted therapy is delivered as preparation + dosing + integration. Preparation is not a formality; it is foundational clinical work.
• Typical preparation structure: 2–4 sessions across 2–6 weeks before the first dosing session, with substantial variation by substance and clinic.
• Preparation accomplishes ten things: comprehensive intake, clinical history review, medication review, therapeutic-alliance building, expectation-setting, trauma-informed psychoeducation, practical planning, anchor / grounding skills, intention-setting, and contraindication screening.
• Substance-specific differences: ketamine prep is typically 1–3 sessions; psilocybin prep follows the Goodwin 2022 COMP001-style protocol of 2–4 sessions with substantial psychotherapy emphasis; MDMA-AT prep is 3 structured sessions per the Mitchell 2021/2023 MAPP1/MAPP2 protocol with heavy emphasis.
• Why it matters: poor preparation is associated with more difficult dosing experiences and weaker integration, across the existing RCT and clinical-observation literature.
• No outcome guarantees: thorough preparation supports safety and quality of the experience but does not predict response. Psychedelic-assisted therapy outcomes remain individualized.

The three-phase model in plain language

Psychedelic-assisted therapy in Canada is delivered as a structured three-phase model: preparation, dosing, and integration. This structure originates in the early MAPS protocols for MDMA-assisted therapy (Mithoefer et al. 2008, 2011), the Imperial College London / COMPASS Pathways psilocybin trials (Carhart-Harris 2016; Goodwin 2022), and the broader ketamine-assisted psychotherapy clinical literature, and it is now the standard frame across reputable Canadian programs.

• Preparation is the work done before the first dosing session: clinical screening, history-taking, education, alliance-building, intention-setting.
• Dosing is the medicine session itself: the patient receives the substance under direct clinical supervision in a prepared therapeutic setting.
• Integration is the work done after dosing: making sense of the experience, translating insights into behaviour change, and consolidating gains over weeks to months.

Each phase is necessary. The substance is one component of the therapy; the relational, cognitive, and behavioural scaffolding around the substance is the rest of it. The preparation phase is the part of the model most commonly under-resourced by patients and under-explained by lower-quality providers, which is why this article exists.

For ATMA CENA's three-phase pathway specifically: preparation + dosing + integration is the operating frame across all substances and coordinated care arrangements, with adaptations to each substance, each patient, and each existing therapeutic relationship.

What preparation actually accomplishes

Preparation is not waiting-room time before the medicine. It is structured clinical work that accomplishes ten distinct objectives. Most patients underestimate this scope before they begin.

1. Comprehensive intake and medical screening

The preparation phase begins with a comprehensive intake. This includes medical history (cardiovascular, endocrine, neurological, hepatic), surgical history, current medications and supplements, allergies, substance use history, and a structured psychiatric history. For ketamine and esketamine specifically, blood pressure baseline and cardiovascular screening are routine. For psilocybin and MDMA, screening for psychotic-disorder personal and family history is non-negotiable.

2. Clinical history review and treatment goals

The clinician reviews prior treatments — pharmacotherapy trials, psychotherapy modalities, dose adequacy, duration adequacy, response and tolerability — and discusses what the patient is hoping to address. This anchors the rest of preparation in concrete, individualized goals rather than generic outcome talk.

3. Medication review and taper considerations

Medication review is one of the most clinically important components of preparation. Taper considerations differ by substance:

• MDMA-AT: SSRIs and SNRIs are generally tapered before MDMA dosing because of pharmacological interaction (reduced subjective effect; modest serotonin-syndrome risk). MAOIs are an absolute contraindication to MDMA. Tapers are physician-supervised and require lead time, which is one reason MDMA-AT preparation runs longer (Mitchell 2021/2023 MAPP1/MAPP2).
• Psilocybin: SSRIs and SNRIs are typically tapered before high-dose psilocybin in research protocols; the COMPASS COMP001/COMP005/COMP006 trials require washout. Lithium is associated with seizure risk in psilocybin co-administration and is a contraindication in most protocols.
• Ketamine: most psychiatric medications can continue concurrently with ketamine and esketamine; benzodiazepines may blunt subjective and antidepressant effect and are sometimes held the day of dosing.

In all cases the prescribing physician makes the taper decision, not the patient. Self-tapering antidepressants without medical supervision is unsafe.

4. Establishing therapeutic alliance with the team

The patient meets the team that will be present in the dosing session and through integration. In MAPS-style MDMA-AT protocols this is a male-female co-therapy pair; in psilocybin protocols it is typically a lead therapist and a co-therapist or sitter; in KAP it is variable. The point of the preparation phase is that the patient enters the dosing session having already established trust with the people who will be in the room.

5. Setting expectations — set and setting

The preparation phase establishes both set (the patient's mindset, expectations, intentions, and current state) and setting (the physical and relational environment of the dosing session). The set-and-setting framework, originally articulated by Leary, Litwin and Metzner (1963) and re-formalized by Hartogsohn (2017), is one of the best-evidenced predictors of psychedelic experience quality. Preparation is where set-and-setting is intentionally constructed rather than left to chance.

6. Trauma-informed psychoeducation

Patients are educated on what the substance does pharmacologically, what subjective effects to expect, what the dose-response curve looks like, and what kinds of phenomena (vivid imagery, emotion surfacing, body sensations, dissociation, ego dissolution at higher psilocybin doses) are normal versus signals to communicate to the team. Trauma-informed framing is critical: the goal is to reduce the chance that intense material in the dosing session is destabilizing rather than therapeutic.

7. Practical planning

The preparation phase covers practical logistics:

• Identifying a support person for transport home and same-day support
• Confirming patient cannot drive after the dosing session
• Booking a post-session day off work
• Scheduling the first integration appointment within 24–72 hours of dosing
• Discussing food, hydration, and what to wear

Skipping practical planning is a common reason a clinically successful dosing session translates poorly into integration.

8. Anchor and grounding skills practice

Patients practice grounding skills — paced breathing, body scans, orienting techniques, simple somatic interventions — before the dosing session. These are the same skills patients can use during dosing if a difficult moment arises. Practicing before the medicine is administered means the patient already has the skill in their nervous system, not merely in their head.

9. Intention-setting

Intention-setting is the patient articulating what they hope to explore, change, or sit with during dosing. Intentions are specific to the patient's goals and are not outcome promises. Common framings: "I want to look at the role of my father in my drinking," "I want to understand my body's signals around the panic attacks," "I want to feel less alone with this depression." Intentions become reference points during dosing and integration alike.

10. Safety and contraindication screening

Comprehensive safety screening is non-negotiable. Standard screens include:

• Psychotic disorder personal history: lifetime psychotic episodes, schizophrenia spectrum diagnoses
• Psychotic disorder family history: first-degree relatives, especially for psilocybin and MDMA
• Cardiovascular: uncontrolled hypertension, recent cardiac event, structural heart disease
• Pregnancy: pregnancy and lactation are contraindications across all substances in current protocols
• Bipolar I disorder: relative or absolute contraindication for psilocybin and MDMA depending on protocol; ketamine evidence base is more nuanced (see ATMA CENA's bipolar-specific guidance)
• Active suicidal ideation with plan and means: requires comprehensive psychiatric assessment, not psychedelic-assisted therapy as first response

These screens are clinical, not bureaucratic. They are the most important reason the preparation phase exists.

How preparation differs by substance

Although the ten functions above apply across psychedelic-assisted therapies, preparation structure differs meaningfully by substance.

Ketamine and esketamine preparation

Ketamine-assisted psychotherapy (KAP) preparation has historically been 1–3 sessions, with less psychotherapy emphasis than psilocybin or MDMA protocols. This reflects ketamine's pharmacology (shorter duration of action, lower risk of destabilizing experience) and its dominant clinical use as a rapid-acting antidepressant. That said, KAP literature increasingly emphasizes preparation: Dore et al. (2019) and Mathai et al. (2023) document outcome differences between psychotherapy-supported ketamine and infusion-only ketamine. For Spravato (esketamine) under the Health Canada label, in-clinic monitoring is mandatory and preparation overlaps substantially with onboarding.

Psilocybin preparation

Psilocybin preparation in current Canadian SAP and research protocols is typically 2–4 sessions over 2–4 weeks with substantial psychotherapy emphasis. The Goodwin 2022 COMP001 trial (NEJM, PMID 36322843) used a structured preparation including initial screening, detailed history-taking, education, intention-setting, and dosing-session rehearsal. The Carhart-Harris 2016 and 2021 Imperial College trials used a similar preparation structure. SAP psilocybin patients in Canada are generally prepared by TheraPsil-trained clinicians or by clinic teams using equivalent psychotherapy frameworks.

MDMA-assisted therapy preparation

MDMA-AT preparation per the Mitchell 2021 MAPP1 (PMID 33972795) and Mitchell 2023 MAPP2 (PMID 37640273) protocols is 3 structured 90-minute preparation sessions before the first dosing session, with heavy emphasis on therapeutic alliance, trauma psychoeducation, and inner-directed approach. This is the longest and most psychotherapy-intensive preparation across the substances. In Canada, MDMA-AT remains accessible only via Health Canada's Special Access Program; SAP MDMA preparation generally follows MAPP-style protocols.

Why preparation matters: what the evidence shows

Preparation is foundational, not optional. Across the controlled-trial and clinical-observation literature, three patterns recur:

1. Poor preparation predicts difficult dosing experiences. Quality of set-and-setting, including the patient's preparation and trust in the team, is among the better-evidenced predictors of subjective experience quality and acute-distress likelihood (Hartogsohn 2017; Carbonaro 2016 on challenging psilocybin experiences, PMID 27909164).
2. Poor preparation predicts weaker integration. Patients who enter dosing without articulated intentions, without practical post-session plans, and without alliance with the team report greater difficulty making sense of the experience and translating it into change.
3. Adverse events cluster in inadequately prepared / inadequately screened patients. Adverse-event reporting in psilocybin and MDMA RCTs concentrates in patients whose contraindication screening was suboptimal.

The Goodwin 2022 COMP001 protocol, the Mitchell 2021/2023 MAPP1/MAPP2 protocols, and the older Mithoefer MDMA protocols all build in 2–6 weeks of structured preparation for reasons supported by trial-level evidence rather than tradition.

This is why ATMA CENA — and reputable Canadian clinics generally — treat preparation as non-skippable clinical work rather than as administrative onboarding.

ATMA CENA's three-phase model and how preparation fits

ATMA CENA's pathway is a three-phase model: preparation + dosing + integration, adapted to substance and to the patient's existing care relationships.

• Preparation length is calibrated to substance and patient: 1–2 sessions for routine KAP onboarding; 2–4 sessions for psilocybin SAP; 3 sessions for SAP MDMA-AT.
• Team continuity: the team a patient meets in preparation is the team in the dosing room and through integration, wherever clinically possible.
• Coordinated care: where a patient already has an existing therapist, psychiatrist, or family physician, ATMA CENA's coordinated care model layers psychedelic-assisted treatment on top of the existing relationship rather than replacing it. The existing therapist can participate in preparation and integration; preparation can include explicit handoff conversations to keep the patient's primary therapeutic relationship intact.
• Informed consent: a structured informed-consent conversation is part of preparation. It covers substance pharmacology, expected and possible effects, risks, contraindications, alternative options (including doing nothing), the limits of evidence, costs, and the patient's right to withdraw at any point.

For pathway detail across substances see Psilocybin Therapy in Canada, Ketamine Therapy in Canada, and MDMA-Assisted Therapy in Canada. For SAP-specific access detail see The Health Canada SAP Application Process — Complete Guide.

What preparation does NOT do

• Preparation does not guarantee a good dosing experience. Even well-prepared patients can have challenging sessions. The team's job is to support the patient through difficult material, not to prevent it from arising.
• Preparation does not guarantee a good outcome. Response to psychedelic-assisted therapy is individualized. Goodwin 2022 COMP001 showed 37% response and 29% remission at the 25 mg psilocybin dose at week 3; meaningful, but not universal.
• Preparation cannot substitute for screening. A patient who does not meet safety criteria cannot be prepared into eligibility. Contraindications are clinical, not motivational.
• Preparation cannot replace integration. Strong preparation makes integration possible; it does not perform integration in advance.

Frequently asked questions

How many preparation sessions will I have? It depends on substance, clinic, and your clinical situation. Typical ranges: 1–3 sessions for ketamine / KAP; 2–4 for psilocybin SAP; 3 for SAP MDMA-AT per MAPP-style protocols. ATMA CENA calibrates preparation length to your specific substance, history, and goals.

Can preparation be done virtually? Some preparation components (intake interviews, history review, education, intention-setting) can be done virtually. Other components — particularly anchor / grounding skills practice with the dosing team, and final clinical clearance — are typically in-person. coordinated care model accommodates blended in-person and virtual preparation.

Do I need to taper my antidepressants before psychedelic-assisted therapy? This is a clinical decision made by the prescribing physician. For MDMA-AT and most psilocybin protocols, SSRIs / SNRIs are generally tapered with medical supervision; MAOIs are an absolute MDMA contraindication. For ketamine and esketamine, most psychiatric medications continue concurrently. Do not adjust psychiatric medications without medical supervision.

What if I have a psychotic disorder in my family? Family history of psychotic disorders is one of the most important screening criteria for psilocybin and MDMA. Personal history of psychosis is generally an absolute contraindication; first-degree-relative family history is a strong relative contraindication, decided on a case-by-case basis. Ketamine has a different evidence profile and is sometimes accessible in patients for whom psilocybin or MDMA is not.

Can my existing therapist be part of preparation? Yes — this is exactly what ATMA CENA's coordinated care model is built for. Your existing therapist or psychiatrist can stay primary, and preparation explicitly includes them where clinically appropriate. See find care near you.

What is "set and setting" and why is it part of preparation? "Set" is the patient's mindset, expectations, intentions, and current state. "Setting" is the physical and relational environment of dosing. The set-and-setting framework, originally described by Leary, Litwin and Metzner (1963) and re-formalized by Hartogsohn (2017), is one of the best-evidenced predictors of psychedelic experience quality. Preparation is where set-and-setting is intentionally constructed.

What if I don't feel ready by the end of preparation? Then the dosing session is rescheduled. Preparation that ends with the patient not ready is preparation working as designed. Pressure to dose is a red flag from any provider.

Is preparation covered by insurance? Coverage is substance- and program-specific. Spravato preparation / onboarding is often covered alongside the medication. KAP psychotherapy hours sometimes attract psychotherapy-benefit coverage. Psilocybin SAP and MDMA SAP are not generally covered by Canadian private insurance. See Insurance Coverage for Psychedelic-Assisted Therapy in Canada.

What is informed consent in this context? Informed consent is a structured conversation covering pharmacology, expected and possible effects, risks, contraindications, alternatives (including doing nothing), the limits of current evidence, costs, and the patient's right to withdraw at any point. It is part of preparation by design — informed consent at the door of the dosing room is too late.

Why is preparation "not optional"? Because every component of preparation has clinical purpose: screening prevents harm; education reduces unhelpful surprise; intention-setting shapes the dosing experience; alliance-building supports difficult moments in the room; practical planning protects the post-session window; informed consent protects patient autonomy. A program that frames preparation as optional is a program that has not internalized the evidence base it claims to operate from.

Compliance disclaimer

This article is educational. Psilocybin and MDMA are Schedule III and Schedule I controlled substances in Canada respectively; clinical access in Canada is via Health Canada's Special Access Program on a case-by-case basis. Ketamine is a Health Canada-approved anaesthetic; psychiatric use is off-label and within Canadian off-label prescribing principles. Esketamine (Spravato) is Health Canada-approved for treatment-resistant depression. Nothing in this article should be construed as a clinical recommendation for a specific individual; clinical decisions belong with a qualified prescribing physician.

Sources

1. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
2. Mitchell JM, Ot'alora G M, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473-2480. PMID: 37640273.
3. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (COMP001). New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
4. Carhart-Harris RL, Bolstridge M, Rucker J, et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry, 3(7):619-627. PMID: 27210031.
5. Carhart-Harris R, Giribaldi B, Watts R, et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15):1402-1411. PMID: 33852780.
6. Mithoefer MC, Wagner MT, Mithoefer AT, et al. (2011). The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology, 25(4):439-452. PMID: 20643699.
7. Carbonaro TM, Bradstreet MP, Barrett FS, et al. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12):1268-1278. PMID: 27909164.
8. Hartogsohn I. (2017). Constructing drug effects: A history of set and setting. Drug Science, Policy and Law, 3:1-17.
9. Leary T, Litwin GH, Metzner R. (1963). Reactions to psilocybin administered in a supportive environment. Journal of Nervous and Mental Disease, 137:561-573. PMID: 14087676.
10. Dore J, Turnipseed B, Dwyer S, et al. (2019). Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. Journal of Psychoactive Drugs, 51(2):189-198. PMID: 30917760.
11. Preller KH, Vollenweider FX. (2018). Phenomenology, Structure, and Dynamic of Psychedelic States. Current Topics in Behavioral Neurosciences, 36:221-256. PMID: 28025814.
12. Health Canada — Special Access Program: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access.html

Related articles

• The Health Canada SAP Application Process — Complete Guide
• The Integration Phase of Psychedelic-Assisted Therapy
• What to Expect at Your First Psychedelic-Assisted Therapy Session
• Coordinated care — ATMA CENA's overlay onto an existing therapeutic relationship
• Psilocybin Therapy in Canada
• Ketamine Therapy in Canada
• MDMA-Assisted Therapy in Canada

Last updated: 2026-05-06